The Optimal Health Manifesto
Home / Peptides / Epithalon
Peptide profile

Epithalon

Epitalon
By Rick Gold
Functional Diagnostic Nutrition (FDN) practitioner
CAnecdotal 🟢Green See the side-effect detail ↓
What do these badges mean?

Evidence tier

  • AHuman-validated — Human trials showing positive results and good safety.
  • BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
  • CAnecdotal — No human or animal trials — only anecdotal/observational reports.
  • DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).

Safety light

  • 🟢 Green — Only mild, manageable side effects; reasonable safety data.
  • 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
  • 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Build a protocol →
Longevity / healthspan
Question 1

What is it?

Epithalon is the telomere peptide. It’s a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled directly on epithalamin, a peptide your pineal gland produces naturally to coordinate the circadian / endocrine / antioxidant systems. The interesting thing about Epithalon isn’t a single dramatic mechanism: it’s that a 4-amino-acid molecule appears to activate telomerase, the enzyme that extends telomeres (the protective caps on your chromosomes), and restores pineal melatonin output, the master timing signal for nearly every biological rhythm you have.

The Hayflick limit, briefly: the problem Epithalon engages. In 1961, biologist Leonard Hayflick and his colleague Paul Moorhead discovered that human cells divide roughly 50–70 times then stop dividing forever: they enter senescence (still metabolically active, no longer functional, secreting inflammatory signals that age the tissue around them) [RESEARCH] ✅ verified 2026-06-13: Hayflick L, Moorhead PS. “The serial cultivation of human diploid cell strains.” Exp Cell Res. 1961;25:585–621. doi: 10.1016/0014-4827(61)90192-6. PMID: 13905658. (The team isolated and characterized 25 strains of human diploid fibroblasts from fetuses and documented the finite cultivation limit later named the “Hayflick limit.”) The reason is telomere shortening: each cell division clips a little off the telomere caps because DNA replication can’t fully copy the very ends of chromosomes. When telomeres get critically short, the cell stops dividing or dies. Short telomeres for your age correlate with higher risk of cardiovascular disease, metabolic disorders, immune dysfunction, and earlier death. Epithalon is one of the very few compounds ever shown to reactivate telomerase in normal human somatic cells — the enzyme that rebuilds telomeres, normally silenced after birth except in reproductive cells and cancer cells. That’s why it’s called the “immortality peptide” — not because it makes anything immortal, but because telomerase reactivation pushes back against the Hayflick limit at the molecular level.

The scientific home of Epithalon is the Russian Khavinson school out of the St. Petersburg Institute of Bioregulation and Gerontology — multi-decade human longevity work in elderly cohorts plus systematic animal lifespan studies, much of it published in the Bulletin of Experimental Biology and Medicine. The Western tier-label is “C/green”: real human data exists, but the methodology and publication venues differ from Western Phase 3 RCT standard. That’s a transparency note, not a disqualifier. The Russian record is the real foundational evidence for Epithalon, the rat lifespan-extension data is consistent across studies, and the mechanism (telomerase + pineal-melatonin) is biologically coherent. Western Phase 3 trials don’t exist because you can’t patent a 4-amino-acid endogenous peptide — funding follows patents, not biology.

The bridge to Western validation now exists (2025). For 20+ years the only direct mechanism evidence for Epithalon in human cells came from Khavinson’s lab in Russia, and Western researchers hadn’t independently replicated it: a legitimate scientific limitation. That changed in September 2025, when a team at Brunel University London — Sarah Al-Dulaimi, Ross Thomas, Sheila Matta, and Terry Roberts: published a paper in the peer-reviewed journal Biogerontology independently confirming that Epitalon increases telomere length in multiple human cell lines through telomerase upregulation OR ALT (alternative lengthening of telomeres) activity ✅ verified 2026-06-13: Al-Dulaimi S, Thomas R, Matta S, Roberts T. “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Biogerontology. 2025 Sep 4;26(5):178. doi: 10.1007/s10522-025-10315-x. PMID: 40908429; PMCID: PMC12411320. A figure-correction notice was later published (Biogerontology 27(1):1; doi 10.1007/s10522-025-10326-8; PMID 41240216) replacing Figs 1-3 with corrected versions — statistical findings unchanged. That’s the bridge from a single Russian lab to Western independent peer review on the core mechanism — two decades later. It’s still early stage, but it exists, and it defuses the most common skeptic objection.

Hold this framing as you read the rest: Epithalon is doing the job a declining pineal gland increasingly can’t do — keep telomeres long, keep melatonin output high, keep the circadian and endocrine timing systems calibrated. It’s compensatory and cycled, not continuous.

Question 2

What does it do in my body?

Four mechanisms: the cleanest single-source delivery comes from Sewell:

1. Telomerase activation → telomere elongation → delayed cellular senescence. Telomeres are the protective caps on chromosomes; they shorten with every cell division, and when they get critically short, cells either die or become senescent — they stop dividing but stay metabolically active, secreting inflammatory cytokines that age surrounding tissue. Epithalon activates telomerase, the enzyme that adds telomeric repeats back to chromosome ends, slowing this clock. One practitioner’s reframe is useful: Epithalon “tells senescent cells to stop their inflammatory temper tantrum and gets functional cells back on the damn job.” The telomerase-activation step is shown in cell culture; the human telomere-length-extension cohort data comes from Khavinson-school work and still needs independent confirmation.

2. Pineal gland regulation → restored melatonin output → circadian/sleep recovery. Your pineal gland produces melatonin from serotonin in response to darkness; melatonin is both the master timing signal for circadian rhythm AND one of the most potent endogenous antioxidants you make, particularly active in the mitochondria. Pineal output declines with age (one of the most reliable age-related biological changes measured). Epithalon, modeled on the pineal’s own epithalamin, restores the pineal’s ability to produce melatonin in the right pattern — which fixes downstream sleep, antioxidant defense, and the entire endocrine axis the pineal coordinates.

3. Direct antioxidant activity → reduced ROS production + reduced oxidative DNA damage. Epithalon reduces free-radical generation and the DNA damage that compounds with it. This is the layer below telomere maintenance — less ROS damage to chromosomes means less telomere attrition in the first place.

4. Immune modulation via telomere integrity + melatonin pathway. Immune cells are some of the highest-turnover cells in your body — they hit replicative senescence faster than most tissues. Restoring telomere length and melatonin output supports immune resilience at the level of “the immune system can keep dividing and responding.” Direct mechanistic link to the Thymosin Alpha-1 immune-restoration story.

The four mechanisms work as a stack, not in isolation: less ROS → less telomere damage → longer telomeres → less senescence → less inflammation → better mitochondrial function → better pineal melatonin output → less ROS. Epithalon engages a positive-feedback loop the body already runs: it’s restoring an aging signal, not adding a foreign one.

Question 3

How can it help me?

  • Best fit: Adults focused on long-term cellular longevity (telomere length, mitochondrial/oxidative biology); chronic insomnia + low melatonin; chronic fatigue with non-restorative sleep
  • Where the science stands: Russian Khavinson-school human longevity cohorts (St. Petersburg Institute of Bioregulation + Gerontology), telomerase-activation cell + animal work, rat lifespan extended ~12–13%, clinical-experiential protocols from peptide MDs

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Question 4 & 5

Is it dangerous? What are the side effects?

Epithalon has one of the lighter side-effect profiles in the peptide space. Sewell summarizes it as “strong safety profile with few reported side effects.”

  • Mild fatigue or dizziness in the first few days of a cycle — usually resolves; mechanism likely the body adjusting to restored melatonin output (sleepiness when the pineal recalibrates).
  • Rare injection-site reactions — minor redness or irritation; rotate sites.
  • Daytime grogginess if dosed too late in the day — the right-before-bed timing exists for a reason; midday dosing can feel sedating. Split AM + PM works for most users.
  • Long-term human safety unknowns: Sewell honestly notes that decades of cycled use exist in Russia, but Western long-term safety data is thinner. The mechanism (telomerase activation) has theoretical implications for any tissue where uncontrolled cell division would be a problem — there’s no human signal of this in the cohort data, but it’s the mechanistic concern people raise and it’s worth knowing about.

No tachyphylaxis. Because Epithalon is dosed in short cycles separated by months, the body doesn’t have the chance to downregulate. Each cycle works because the previous one ended cleanly.

The product-quality concern is the real one. Like every other peptide, the variable risk isn’t the molecule — it’s whether the vial actually contains what the label says. See the Alyve section below for the verified-vendor framing.

The cancer question — steelman then rebut, four points (added 2026-08-02, from Tatem)

The mechanistic concern any reader will surface: telomerase is one of the tricks cancer cells use to divide forever — either by switching hTERT on directly or through the backup ALT (alternative lengthening of telomeres) route. The Al-Dulaimi 2025 Brunel paper (PMID 40908429) already carried in this wiki explicitly documents that Epitalon lengthens telomeres in breast-cancer cell lines through the ALT route. So no — the cancer question is not imaginary. But four points bound how heavily to weigh it:

1. “Telomerase is ON in cancer” does not mean “turning telomerase ON causes cancer.” Telomerase is on in your stem cells. It’s on in your immune cells every time you fight off an infection. It’s on in a developing embryo. It’s a normal, regulated, repair tool your body uses constantly. A real tumor isn’t a cell that flipped one switch — it’s a cell that has stacked up a pile of broken systems (ignores stop signals, dodges the immune system, rewires its own metabolism, AND props up its own telomeres). Telomere maintenance is one ingredient in a very ugly recipe — putting flour on your counter does not bake a cake.

2. Exercise activates telomerase 2–3× — and it doesn’t cause cancer, it prevents it. ✅ verified 2026-08-02 — Werner CM, Hecksteden A, Morsch A, et al. “Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study.” Eur Heart J. 2019 Jan;40(1):34-46. DOI: 10.1093/eurheartj/ehy585. 4-arm RCT in 266 previously-inactive young healthy volunteers (endurance / HIIT / resistance / control), 3× 45-min sessions/week × 6 months. The endurance and HIIT groups showed 2–3× telomerase activity increase + significant telomere lengthening. Resistance training did NOT produce the effect. Control did NOT. Aerobic-tier training turns telomerase on the same way peptide-influencer content warns against — and cardiovascular exercise prevents multiple cancers. If activating telomerase caused cancer, endurance runners would have more cancer, not less. They don’t. The mechanism was never the villain — context is.

3. The best in-vivo Epitalon signal in a cancer-prone model runs the OPPOSITE direction to the fear. The wiki’s already-pinned HER-2/neu study — Anisimov et al. Bull Exp Biol Med 2002. PMID 12459848 — administered Epitalon to female transgenic FVB/N mice carrying the HER-2/neu breast-cancer transgene (mice that develop spontaneous mammary tumors young). Results: +13.5% mean lifespan, breast-adenocarcinoma incidence -1.6×, multiple-tumor incidence -2×, mice with 0 breast tumors 3.7× more, HER-2/neu mRNA in mammary tissue -3.7×. In a genetically cancer-prone whole animal, Epitalon reduced tumor burden while extending lifespan. This is the strongest preclinical mammalian in-vivo evidence on the cancer question — and it doesn’t support the “telomerase activator = cancer risk” fear at the whole-organism level. It complements the Brunel 2025 finding that Epitalon uses telomerase in normal cells and ALT in already-transformed cancer cells: the cell-line mechanism split translates in vivo to net protective rather than net promoting.

4. Burden of proof cuts both ways — there’s no published case series of Epitalon-caused cancer in humans. Despite decades of Russian clinical use + years of US gray-market use, the published human-adverse-event record on Epitalon-associated cancer doesn’t exist. Absence of evidence is not evidence of absence — but the fear-mongering side of this argument owes evidence, not just mechanism-plus-narrative.

Where this lands. Technically an unknown with a likely anti-cancer bend at the whole-organism level. The explicit exclusion criteria that DO make sense: if you have an active cancer, a recent cancer, or a known genetic predisposition like a BRCA1 or BRCA2 mutation, this probably isn’t your peptide — talk to your oncologist before considering it. Don’t poke the telomerase-maintenance bear when you already have cells trying to cheat death.

For everybody else, the primary-literature signal doesn’t support the strongest fear-mongering framing. It’s a personal decision informed by an actual medical provider who knows your specific labs, family history, and goals (provider directory) — not one that OHM should either dismiss or catastrophize. Under Rick’s 2026-08-02 range-reporting doctrine, both the honest cancer-caveat (Kuo 2019, above) AND the honest cancer-counterweight (Werner 2019 + Anisimov 2002 + no published adverse-event case series) belong on the page.

Regulatory status: Not FDA-approved for any indication. Sold in the US as a research chemical, “not for human consumption.” Not on the WADA prohibited list (telomerase activation isn’t directly performance-enhancing in the WADA sense). Long history of clinical use in Russia under Khavinson-school protocols.

Preparing it

Part 1 — How to reconstitute it

What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.

Reconstitution math. Epithalon ships as lyophilized vials, commonly 10 mg or 50 mg. For a 10 mg vial reconstituted with 1 mL bacteriostatic water, you get 10 mg/mL — and 5 mg = 0.5 mL = 50 units on a U-100 insulin syringe. For a 50 mg vial reconstituted with 2 mL bac water, you get 25 mg/mL — and 10 mg = 0.4 mL = 40 units. Inject water down the side of the vial, swirl — don’t shake. Reconstituted, store in the fridge; Epithalon is reasonably stable for the duration of a 10–20-day cycle.

How to mix it

  • Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
  • Swirl gently to dissolve. Never shake — shaking can damage the peptide.
  • Store the reconstituted vial refrigerated and out of light.
  • Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.

Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.

Dosing

Part 2 — Typical dosing

Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.

The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.

The Epithalamin–vs–synthetic-Epitalon anchoring question. The original Russian human cohort trials that produced most of the widely-cited efficacy data used Epithalamin — a crude bovine pineal extract, a mixture of many polypeptides at the total dose reported. The synthetic tetrapeptide Epitalon (AEDG, Ala-Glu-Asp-Gly) was later isolated as the active fragment inside that mixture, and it’s the compound sold today. Practitioner protocols in the 5–10 mg/day range are anchored to Epithalamin trials; the synthetic-Epitalon primary literature documents doses in the microgram range in animal studies + one 0.5 mg/day sublingual human circadian trial (n=75 women × 20 days) — see the 2025 IJMS review below. Whether the correct synthetic-Epitalon protocol maps to the Epithalamin doses at a 1:1 or a lower ratio is the exact question that splits the practitioner-source table.

OHM does not pick a single “correct” protocol on behalf of the reader. Where credentialed practitioners disagree — as they do on Epithalon — OHM captures every position honestly with its supporting evidence tier, and the reader (with their prescribing clinician) chooses. The section below reflects that stance.

The active dosing debate. Two distinct practitioner camps report protocols separated by roughly an order of magnitude, and both cite the same peptide molecule. The disagreement traces to a specific historical fact worth understanding before reading the table:

The range of practitioner protocols (each row is a documented practitioner position with the evidence behind it — presented as a range, not as a ranking):

Source Dose Per-cycle Cycle frequency Anchoring rationale
Sewell 5–10 mg/day SubQ, split into 2 doses 10–20 days Every 4–6 months Sleep protocol leans 5 mg 2×/day × 10 days; telomere protocol leans 10 mg/day × 20 days. Anchored to the Epithalamin-era community-standard range.
one practitioner ~10 mg/day (personal) 20 days 3 times per year Dosed right before bed — likely pineal-melatonin synchronization. Same order of magnitude as Sewell.
Sawicki 0.5–1 mg/day synthetic Epitalon 10–20 days 2–3× per year Explicitly flags the Epithalamin-vs-synthetic-Epitalon distinction as the reason the 5–10 mg number overstates the dose the pure AEDG tetrapeptide needs.
Holyfield (revised 2026-08-01) 500 μg – 1 mg/day synthetic Epitalon 10–20 days 2–3× per year Public retraction of his prior 10 mg framing (2:54 correction Short 2026-08-01). Explicitly names the Epithalamin-vs-synthetic-AEDG anchoring error and states the “500× less” quantitative claim (specific multiplier unpinned; direction supported by the primary literature).
Trigili (n=1, cycle 1) 1–2 mg/day SubQ (later cycles widened to 2–10 mg) 21 days per cycle × 10 cycles over 5 years 2–3× per year Reported “absence of fog” cognitive effect + compounding benefits across cycles. His first-cycle dose sits at the low-dose boundary.
Tatem (added 2026-08-02) Low-dose sleep camp: a few hundred μg / night (with some users going as low as 10 μg). Explicitly identifies the 5–10 mg/day camp as “almost always secretly misquoting an epithalamin number.” Nightly / short cycles on the low-dose framing — Third practitioner-source publicly naming the Epithalamin-vs-synthetic anchoring error (joins Sawicki + Holyfield-revised). “Chicken nugget vs whole Thanksgiving turkey” analogy for the Epithalamin-vs-synthetic dose confusion. Also anchors the low-dose framing on the 75-women 0.5 mg/day sublingual trial’s 1.6× urinary 6-AMTS outcome (see the Measurable endpoints subsection below).

Primary-literature synthetic-Epitalon doses (independent of any practitioner protocol), from the newly-added 2025 Western peer-reviewed review — Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. “Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties.” Int J Mol Sci. 2025. PMID: 40141333. PMCID: PMC11943447. ✅ verified 2026-08-01:

  • CBA mice (lifespan): 0.1 μg/mouse × 5×/week
  • Wistar rats: 0.5 μg/rat × 30–42 days
  • Campbell rats (retinal, parabulbar): 1 μg/rat × 72 days
  • Human retinitis pigmentosa (n=162): 5.0 μg per eye × parabulbar × 10 days
  • Human circadian-rhythm study (n=75 women): 0.5 mg/day × sublingual × 20 days — the direct human anchor for a sub-milligram synthetic-Epitalon protocol.

Reconciliation note on the Anisimov 2002 HER-2/neu study (already cited in the “Animal / preclinical” section above): the 2025 review restates the dose as “1 μg/mouse × 5×/week”; the PubMed abstract for that study reads “1 mg SubQ 5×/week” (verified 2026-08-01). A 1000× discrepancy. The PubMed abstract is authoritative — the wiki uses the mg figure per the primary source; the 2025 review appears to carry a transcription error on that specific data point. Full-text access to Anisimov 2002 would settle it definitively.

Route and timing. SubQ is the most-reported route across the practitioner-source table; sublingual is documented in the 75-women circadian trial. Right-before-bed dosing (one practitioner’s protocol) has a plausible pineal-melatonin-synchronization rationale but has not been compared head-to-head against AM-only dosing in a published trial.

Measurable endpoints — what to test to know if it’s actually working (added 2026-08-02, from Tatem)

Test urinary 6-sulfatoxymelatonin (6-AMTS), not telomere length. 6-AMTS is the primary breakdown product of melatonin — roughly 90% of nightly melatonin production is excreted as 6-AMTS in urine, and it’s a validated, orderable clinical test at Quest and most other big commercial labs. Your first-morning urine sample tells you approximately how much melatonin you produced overnight. Measure pre-cycle, measure again during or immediately after the cycle. The 75-women sublingual trial detailed above hit a 1.6-fold increase in urinary 6-AMTS after 20 days at 0.5 mg/day sublingual — that’s the reference magnitude for what a real Epitalon-driven melatonin increase looks like at that specific dose/route.

Why not test telomere length instead? Commercial telomere-length tests exist (TeloMe, Life Length, SpectraCell, Repeat Diagnostics), but there are two honest problems: (a) test-retest reliability in a single individual over a single cycle is poor — the noise floor is often bigger than the effect size the peptide would plausibly produce, so a difference between two measurements is more likely to be measurement noise than a real biological change; (b) even if the length change is real, whether that translates to healthspan is a separate open question — see the next subsection on Kuo 2019. Chasing a telomere-length number that may not mean what the marketing implies is a worse use of the reader’s dollars than measuring 6-AMTS on a cheap validated commercial test.

Longer telomeres ≠ longer/healthier life — the anti-hype primary-literature anchor (added 2026-08-02)

The single strongest published-literature caveat on the Epitalon-marketing narrative. ✅ verified 2026-08-02 — Kuo CL, Pilling LC, Kuchel GA, Ferrucci L, Melzer D. “Telomere length and aging-related outcomes in humans: A Mendelian randomization study in 261,000 older participants.” Aging Cell. 2019 Dec;18(6):e13017. PMID: 31444995. PMCID: PMC6826144.

What Mendelian randomization tests here. Some people are born with gene variants that give them longer telomeres their entire life — a natural experiment approximating the counterfactual “what happens if you had this treatment lifelong?” that a real trial can’t run in a reasonable timeframe. This UK Biobank cohort of 261,000 European-ancestry 60-70-year-olds followed 7.5 years is one of the largest tests of this specific question ever run.

What Kuo 2019 actually found:

Outcome Effect of genetically longer telomeres
Coronary heart disease Lower risk — OR 0.95, 95% CI 0.92–0.98
Cancer Higher risk — OR 1.11, 95% CI 1.06–1.16
Grip strength No benefit
Cognitive function No benefit
Sarcopenia No benefit
Falls No benefit
Parental lifespan No benefit
Parental centenarian status No benefit

Authors’ own conclusion (verbatim from the paper): “presence of a risk of excess cancer in those with genetically longer telomeres poses a major hurdle in harnessing telomere lengthening to prolong human lifespan.”

Honest editorial framing per Rick’s 2026-08-02 “OHM reports the range” doctrine. OHM reports the range of practitioner-source positions on Epitalon dosing + cycling (see the range table above). OHM also honestly reports that the endpoint most practitioners cite — telomere lengthening — doesn’t automatically translate to the outcome customers actually want, which is longer healthier life. Both belong. Kuo 2019 does not say Epitalon is useless. It says the specific “longer telomeres = longer life” chain the marketing implies isn’t supported by the strongest available human evidence — and it flags a specific cancer-signal caveat that anyone considering Epitalon should know about. The next subsection walks through the practitioner-side steelman-then-rebut on the cancer question in detail; both readings live in the wiki honestly.

What’s not disputed across the range. Every practitioner-source in the table cycles Epithalon — nobody advocates continuous daily use. Cycle length converges on 10–30 days per cycle; cycle frequency converges on 2–3 times per year. The cycled-not-continuous protocol shape is the consensus even where the per-day dose isn’t.

Talk to your prescribing clinician. This section reports the range of practitioner recommendations and the primary-literature dose data behind them. It does not choose the protocol for you. A peptide-literate clinician who knows your baseline labs, meds, and goals is the right person to route the individual decision on where inside this range to sit (provider directory).

Oral admin is possible but inferior. Sewell notes oral Epithalon works but SubQ is preferred for “higher bioavailability.” The oral-vs-SubQ gap isn’t quantified. If you have any reason to inject, inject — but oral isn’t a useless route the way it is for SS-31 (Elamipretide).

Lab monitoring (Sewell’s clinical framework).

  • Baseline: CMP + CBC + sleep study if applicable.

  • Anti-aging biomarker: telomere length (TeloMe / Life Length / SpectraCell accuracy + cost) — optional but useful for tracking actual telomere response to cyclic Epithalon over a year.

  • Inflammation: CRP.

  • Patient-reported outcomes: energy, sleep quality, cognitive function — Sewell notes these are “the most actionable monitoring metrics” in practice.

  • NAD+ — NAD+ precursor pathway supports the same mitochondrial / oxidative biology Epithalon operates on; Anderson’s clinical sequencing protocol pairs cleanly with cyclic Epithalon.

  • MOTS-c — mitochondrial-derived peptide; ATP / insulin-sensitivity layer. Epithalon (genomic) + MOTS-c (metabolic) is the genomic + mitochondrial restoration pair.

  • Thymosin Alpha-1 — immune-cellular replicative capacity (telomere integrity supports immune-cell division capacity). Cross-mechanism synergy.

  • BPC-157 — tissue repair / firefighter. Different layer; same forever-stack rationale.

  • The “four-peptide forever stack” (MOTS-c + Epithalon + BPC-157 + TA1) addresses metabolism + genome + repair + immune in one bundle.

  • GHK-Cu — collagen / skin / hair / nail regenerative biology; pairs well as the visible-aging layer alongside the cellular-aging biology Epithalon addresses.

Cycling philosophy. Epithalon is explicitly cycled, not run continuously. The mechanism is biological re-calibration — a 10–20-day pulse engages the telomerase + pineal restoration, and the body runs with that effect over the following months before the next pulse. Continuous daily Epithalon is not the protocol.

Question 7 & 8

What should I avoid combining — and what's synergistic?

Stacking: the natural longevity cluster.

Question 9

How can I buy this?

Epithalon is available from US Pure Peptides — use code OHM20 for 20% off. US-manufactured, ISO 17025-accredited third-party COA testing on every batch, free bacteriostatic water included.

Epithalon is also available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.

When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.

Sources & references

  • clinical-protocol-training source. The cleanest single-video Epithalon dosing + lab-monitoring + case-studies + alternative-pathway map in the KB.
  • Epithalon depth (telomerase activation + Russian Bulletin of Experimental Biology + Medicine as primary literature anchor, 12–13% rat lifespan extension figure, “stop the inflammatory temper tantrum” framing), one practitioner’s personal protocol (3× per year × 20 days × right before bed), four-peptide forever stack rationale.
  • (added 2026-06-12) — Sean / PeptideAtoZ ~9:28 beginner-friendly mechanism explainer. Highest-value contribution: clean institutional + journal + first-author identification of the September 2025 Brunel University London paper in Biogerontology (Alaimi et al., exact spelling + ) — the first independent Western peer-reviewed confirmation of Khavinson’s 2003 telomerase / telomere mechanism in human cells, plus the ALT-pathway secondary mechanism. Also supplies the Hayflick 1961 / 50–70 divisions historical anchor + the “bridge from Russian to Western validation now exists” editorial framing OHM should anchor on. Anti-hype educational voice — unusually aligned with OHM tone, minimal voice-strip needed; direct-quote candidates throughout for the OHM Epithalon page intro.
  • Sawicki PhD-grade mechanism deep dive. The “six aging hallmarks Epithalon touches” framework, the 4-cell-line cancer-cell ALT-activation finding (likely the same Brunel 2025 paper Sean PeptideAtoZ identifies — closes Sawicki’s citation gap), the direct DNA + histone binding (H1/H2B/H3/H4) chromatin-loosening mechanism, the 75-woman sublingual circadian-gene-expression human trial, the NRF2/SOD/catalase/NQO-1 antioxidant pathway, the IL-2 / CD4-CD8 immune-rejuvenation specifics, the neuroprotection mechanism stack (reduced 8-OHdG, increased soluble APP, AChE/BuChE activity, fibroblast-to-neuron differentiation), HER2/neu mouse breast cancer model results. Critical: Sawicki surfaces the Epithalamin (bovine pineal mixture, the original Russian extract) vs synthetic Epithalon AEDG dosing contradiction — early 10 mg doses came from the mixture; pure synthetic Epithalon may need a fraction. Unresolved in the wiki until primary-literature pass. See VERIFY queue below.
  • Holyfield clinical case framing + the famous 12-year CVD trial (n=79, 10 mg injections per Holyfield — was previously the counterweight in the dosing contradiction) + dual-system mechanism naming convergence with Sean’s framing. ⚠️ Practitioner has publicly retracted the 10 mg dosing framing 2026-08-01 — see. Holyfield now recommends 500 μg – 1 mg/day for synthetic Epitalon, explicitly citing the Epithalamin-vs-synthetic anchoring error. The 12-year CVD trial’s exact dose specifically is not re-examined in the correction video — needs on whether the “10 mg” figure Holyfield cited was Epithalamin (mixture) or synthetic Epitalon (AEDG).
  • (added 2026-08-02) — Dr. Alex Tatem (board-certified urologist + men’s-health specialist, already an established KB source practitioner) 25:48 YouTube deep-dive titled “The Fountain of Youth Peptide? The Truth About Epitalon.” Most content-dense practitioner overview in the Epitalon corpus since the June 2026 Sewell/one practitioner/Sawicki cluster. Load-bearing contributions: (a) third practitioner-source publicly naming the Epithalamin-vs-synthetic anchoring error (Tatem’s “chicken nugget vs whole Thanksgiving turkey” analogy) — joins Sawicki + Holyfield-revised on the low-dose side of VERIFY item #9; describes the community’s aggressive-telomere-protocol camp (5-10 mg/day) as “almost always secretly misquoting an epithalamin number”; (b) new quantitative anchor for the 75-women sublingual trial: 1.6-fold urinary 6-AMTS increase at 0.5 mg/day × 20 days — plus Cry2 doubled + Csnk1e down 2.1-fold on clock-gene modulation; population = 40-59-yr night-shift-working women (doctors + nurses) with documented reduced pineal melatonin-forming function; probable citation Khavinson VK, Linkova NS, Ivko OM 2021 (exact unpinned this session,); © 6-sulfatoxymelatonin (6-AMTS) as the practical measurable endpoint — validated urinary melatonin metabolite, orderable at Quest and most big commercial labs, first-morning urine sample; drives the new Measurable Endpoints subsection; (d) Kuo 2019 anti-hype primary-literature anchor — Mendelian randomization on 261,000 UK Biobank participants aged 60-70 followed 7.5 years, genetically longer telomeres → lower CHD (OR 0.95) but HIGHER cancer (OR 1.11) + no benefit on grip strength / cognitive function / sarcopenia / falls / parental lifespan / centenarian status; authors’ conclusion verbatim: “presence of a risk of excess cancer in those with genetically longer telomeres poses a major hurdle in harnessing telomere lengthening to prolong human lifespan”; (e) Werner 2019 European Heart Journal endurance-training telomerase RCT — 266 previously-inactive volunteers, 4-arm (endurance / HIIT / resistance / control), 3× 45-min sessions/week × 6 months; endurance + HIIT groups showed 2-3× telomerase activity increase + significant telomere lengthening; resistance training did NOT; control did NOT; anchor for the cancer-question point #2 (if activating telomerase caused cancer, endurance runners would have more cancer, not less); (f) new four-point steelman-then-rebut framework on the cancer-risk question; (g) explicit exclusion criteria — active cancer / recent cancer / BRCA1-2 mutation → probably not your peptide, talk to your oncologist. Practitioner-bias overlay applies (Tatem sells clinic consultations + merch; the video is top-of-funnel content) — captured for source-tracking; the science + editorial framework are OHM-voice-aligned and don’t require the fear-based-framing strip most practitioner sources do.
  • (added 2026-08-01) — Josh Holyfield 2:54 YouTube Short titled “I Got The Epitalon Dosing Wrong.” Public correction of the 5–10 mg/day dosing framing that appeared in his prior deep-dive video. Names the Epithalamin (crude bovine pineal extract, mixture of many polypeptides at that total dose) vs synthetic Epitalon (isolated 4-amino-acid AEDG) distinction as the origin of the anchoring error — Epithalamin-anchored numbers got repeated as-if-equivalent for the synthetic tetrapeptide, which is a category error. Revised recommendation: 500 μg – 1 mg daily × 10 to 20 days for the synthetic Epitalon (AEDG) available today. Route not specified in the correction video (SubQ or sublingual would both be supportable per the primary literature). Also states the “500× less” quantitative claim — on the specific 500:1 arithmetic; the direction is supported by the 2025 Araj et al. IJMS review’s documented μg animal doses + 0.5 mg/day sublingual human trial (n=75 women), but a specific head-to-head Epithalamin-vs-Epitalon efficacy paper with an explicit 500:1 ratio was not found in this session. Holyfield is now on the same low-dose side as Sawicki, so the practitioner-source score has shifted — Sawicki + Holyfield (revised) on the low-dose side; Sewell + one practitioner on the 5-10 mg side. Editorial voice worth noting for future OHM voice-model references: “do your own research, verify your sources… approach science with humility… prove yourself wrong, not right” — closest practitioner-source voice to OHM’s own SOURCE-DIGEST-RULES doctrine. Practitioner-bias overlay applies (Holyfield runs a paid coaching community, linked in the description), but in this video the pitch is soft and the point of the video is a public retraction — cuts against a pure sales-funnel read. Load-bearing: this is the single most consequential dosing-side wiki update since the Brunel 2025 verification. New anchoring citation added to the wiki: Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Int J Mol Sci 2025. PMID 40141333; PMCID PMC11943447. Also flags a reconciliation — the 2025 IJMS review restates the Anisimov 2002 HER-2/neu study dose as “1 μg/mouse × 5×/week” while the actual PubMed abstract for that study (verified 2026-08-01) reads “1 mg SubQ 5×/week”; the PubMed abstract is authoritative and the wiki uses the mg figure per the primary source.
  • one practitioner’s longevity-stack framing + telomerase narrative.
  • Sawicki’s prior sleep-context Epithalon mention; cross-link to DSIP + future circadian-sleep branch.
  • (added 2026-06-13) — 25-second YouTube Short from anonymous “oral peptides” channel; no speaker identification, no credentials, no source citations. LOW source-credibility tier, captured per OHM “capture-everything” doctrine. Single corroborating data point on the 10 mg side of the open dosing contradiction (10 mg/day × 10-20 days × every 3-6 months: uses “hypothetical mouse experiment” deniability framing standard in the peptide-content niche). Also captures the “ticking time bomb / snooze button” telomere analogy as a beginner-grade framing usable in OHM consumer content with anonymous-channel attribution. Route ambiguity flag: channel name “oral peptides” raises the unconfirmed possibility of an oral-route protocol; before treating as SubQ-side data. DO NOT propagate the 10 mg dosing as standalone authority from this source — reference Sewell + one practitioner + Holyfield as the anchors; this Short just corroborates.
  • (added 2026-06-13) — 50-second YouTube Short from anonymous “Peptide Insights” channel; no speaker identification or credentials. LOW source-credibility tier, captured per OHM “capture-everything” doctrine. Net contribution: one meaningful editorial reframe. Instead of debating Epithalon dosing at the per-day-dose level (which is where Sewell/one practitioner/Holyfield vs Sawicki disagreement lives), reframe as total-cycle-dose (50-100 mg) ÷ cycle-length (10-20 days) = per-day dose. The total-cycle-dose continuum maps the existing source disagreement legibly (table inserted above) and gives OHM content a cleaner authority-content frame than “practitioners disagree, you pick.” Also implicitly invokes the Khavinson cycled-bioregulator class doctrine (“This is a pretty common thing I’ve seen with most bioregulators”) — connecting Epithalon’s protocol shape (short pulse / spaced rest) to the broader the Khavinson bioregulator family doctrine. DO NOT propagate the specific 50-100 mg number as standalone authority from this source — reference Sewell as the authority anchor (his 5-10 mg/day × 10-20 days math overlaps this Short’s range at the high end); this Short just adds the editorial reframe. Arithmetic-based reframe doesn’t require source authority; the framing connector does.
  • (added 2026-08-01) — Nicholas Trigili (Human Performance Specialist channel, paid biohacking-coaching program) 12:49 n=1 experiential report on running Epitalon 10 times over 5 years, tracked on Whoop + Apple Watch + Eight Sleep. Practitioner-bias overlay applies (top-of-funnel content for a paid coaching program). Nothing new on the mechanism side — the science block maps 1-for-1 onto the existing wiki spine (Khavinson origins, telomere/telomerase, pineal/melatonin, bioregulator-class doctrine). What this digest earns its keep on: (1) the “absence of fog” phenomenology — the cleanest single-line description in the KB corpus of what the cognitive effect actually feels like (“you don’t feel Epitalon working. You feel the absence of a drag you’d normalized for years”, paraphrased for OHM voice per the 2026-06-18 no-verbatim-quotes rule); (2) the Adderall-alternative content angle — new authority-content hook for OHM’s burnout / cognitive-fog / anti-stimulant-dependence audience, with the important editorial boundary that this is a root-cause-repair-frame narrative for chronically-under-recovered healthy adults, NOT an ADHD-substitution claim; (3) the 10-cycle longitudinal shape — most existing case-studies in the KB are 1–3 cycle vignettes, Trigili’s arc runs across 5 years and corroborates the “benefits compound over cycles” pattern already documented in epithalon-community-reports.md; (4) a fresh dose-side data point on the low-dose (Sawicki-side) of the wiki’s open Epithalamin-vs-synthetic-Epithalon dosing contradiction — Trigili’s first cycle was 1–2 mg/day × 21 days; VERIFY item #9 remains open but the low-dose corroboration is captured; (5) a 4-peptide cognitive-longevity sequencing stack — Epitalon → Pinealon → Semax + Selank as a documented n=1 protocol variant, distinct from the wiki’s existing MOTS-c + BPC-157 + TA1 mitochondrial+repair+immune cluster (both share Epitalon as anchor). Cross-linked into epithalon-community-reports.md this session. on Trigili’s “over 7,000 papers declassified” and “16 million Americans on Adderall daily” claims — both unsourced, the 16M-daily figure is inconsistent with CDC / IQVIA numbers (~40M annual scripts, ~4.9M daily users as of 2013); DO NOT propagate either number to customer-facing OHM content without a real source.
  • (added 2026-08-01) — Dr. Max MacCloud (ARTC channel) 5-minute beginner-friendly educational overview. Content is not new — it retells the existing wiki spine (Hayflick → telomerase → Khavinson 2003 → Brunel 2025 → pineal/melatonin → animal longevity + honest human-gap caveat) — but it pinpointed three primary-literature citations the wiki carried implicitly, and a targeted PubMed pass this session verified all three: (1) Drosophila lifespan +11–16%: Khavinson et al. Mech Ageing Dev 2000;120(1-3):141-149 (PMID 11087911); (2) rhesus-monkey pineal / endocrine restoration: Goncharova et al. Exp Gerontol 2005;40(1-2):51-57 (PMID 15664732); (3) HER-2/neu transgenic mice — +13.5% mean lifespan, +13.9% max, 3.7× fewer breast tumors in a cancer-prone model: Anisimov et al. Bull Exp Biol Med 2002;134(2):187-190 (PMID 12459848). The HER-2/neu finding is load-bearing for the OHM cancer-safety framing — in a genetically cancer-prone whole animal, Epithalon reduced tumor burden while extending lifespan, complementing the Brunel 2025 telomerase/ALT cell-line specificity. Zero contradictions with the existing wiki. No practitioner-bias overlay (MacCloud does not sell a program or clinic inside the video). Speaker’s “Sara Aldama” pronunciation of the Brunel 2025 first author is a third mispronunciation of Al-Dulaimi — same paper, same authors, already pinned.
  • Epithalon graded C/green PRIMARY longevity, Khavinson-school primary anchor; flagged as strong catalog-expansion candidate.
  • confirmed Epithalon is NOT in current 15-SKU catalog.

Related: Thymosin Alpha-1 · MOTS-c · NAD+ · SS-31 (Elamipretide) · BPC-157 · GHK-Cu.

Community experience reports

Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.

Companion raw digest:; extended 2026-08-01 with. Evidence tier: throughout Last updated: 2026-08-01 (extended with Trigili n=1 10-cycle arc + Adderall-alternative cognitive-fog framing + 4-peptide sequencing stack). Cross-refs: [DSIP](/peptides/dsip/) · [SS-31 (Elamipretide)](/peptides/ss-31/) · [MOTS-c](/peptides/mots-c/) · [Pinealon](/peptides/pinealon/) · [Semax](/peptides/semax/) · [Selank](/peptides/selank/) · *bioregulators-khavinson-cluster* · *circadian-sleep*

Who reports the strongest results

Anti-aging and longevity-focused users — people building a long-term biological age optimization strategy, not seeking an acute performance effect. Epithalon is primarily sought for its telomerase activation mechanism (long-term) and its reliable sleep architecture improvement (immediate).

What the community actually says

The immediate signal: sleep architecture

Despite being marketed primarily as a longevity peptide, sleep quality improvement is the most consistent early community experience — and it’s measurable.

  • Deep sleep and REM percentage improvements documented by Oura Ring users: one widely-referenced account showed REM rising from 18% to 23% of total sleep time within a single 10-day cycle
  • Sleep described as deeper and more restorative within the first week
  • More vivid dreams (typically pleasant) in early cycle days

This immediate sleep signal gives users actionable confirmation that the peptide is doing something — important for a molecule whose longevity mechanism (telomere lengthening) can’t be felt.

The long-term orientation

Community members who track biological age markers, energy trajectories, and recovery capacity over years describe cumulative improvements across multiple epithalon cycles. The second cycle often feels more impactful than the first. Benefits compound.

This cumulative-build pattern is unusual — community treats it differently from peptides that require ongoing dosing for sustained effect.

The Fred Cloud dosing lesson

Fred Cloud’s documented experience: positive sleep improvement at standard doses; paradoxical insomnia at higher doses; return to positive effect at lower dose on subsequent cycle. This specific finding circulates in every dosing thread. Start at 5 mg/day, not 10 mg, until individual tolerance is established.

The Trigili 10-cycle arc — a documented longitudinal n=1 (added 2026-08-01)

Context: Nicholas Trigili (Human Performance Specialist channel, personal-coaching program) reports running Epitalon 10 times over 5 years, self-tracked on Whoop + Apple Watch + Eight Sleep. This is one of the few documented multi-year multi-cycle n=1 arcs in the KB, so its longitudinal shape is worth capturing separately from single-cycle vignettes. Source:. Practitioner-bias overlay applies (Trigili sells a coaching program), captured for source-tracking; the arc itself is — one person, self-tracked wearables, no controls, no blinding.

Cycle 1 (5 years before filming — his baseline case):

  • Dose: 1–2 mg/day SubQ × 21 days, right before bed. Notably low — sits on the same low-dose side as Sawicki’s 0.5–1 mg/day range in the main Epithalon article’s open dosing-contradiction table, not the Sewell/one practitioner 5–10 mg/day range. Another data point on the Epithalamin-mixture-vs-synthetic-AEDG open question.
  • Days 7–10: deeper sleep, faster sleep onset, more vivid dreams. Wearable trackers registered the changes.
  • Weeks 2–3: recovery improved, nervous system calmer + less reactive, mood + emotional regulation shifts.
  • The cognitive effect he can name: “the absence of fog” — not a stimulant lift, but the removal of a drag he’d normalized without realizing he was operating under it. Paraphrased for OHM voice: “You don’t feel Epitalon working. You feel the absence of a drag you’d normalized for years.” This is the phenomenologically cleanest description of the Epitalon cognitive effect in the KB.

Cycles 2–10 (dose trajectory + compounding pattern):

  • Later-cycle range widened to 2–3 mg/day at the low end, up to 5–10 mg/day SubQ.
  • Cycle length 20 / 30 / 45 days, 2–3× per year max — matches the wiki’s Sewell/one practitioner cycling convention.
  • Compounding-over-cycles pattern: benefits with sleep, cognitive function, and focus reported to compound over time even during off-cycle periods — corroborates the “second cycle often feels more impactful than the first” pattern already in this file.
  • No tolerance, no rebound, no withdrawal across 10 cycles — matches the wiki’s side-effect profile.

The Adderall-alternative framing — Trigili’s video is centered on the story of using Epitalon to get off Adderall dependence after years of stimulant burnout. He frames Epitalon as a root-cause repair signal rather than an acute performance-enhancer: stimulants force output out of a system that’s already broken; Epitalon addresses what’s breaking down underneath… Careful boundary for OHM content: this framing works as an anti-stimulant-dependence / burnout-recovery narrative for a healthy adult who’s been chronically under-recovered. It does NOT translate to “Epitalon treats ADHD” — that would be a mechanistic and clinical overreach. Use the empowering root-cause frame; do NOT market as an ADHD substitute.

The 4-peptide cognitive-longevity sequencing stack (Trigili) (added 2026-08-01)

Trigili’s documented n=1 stack is a cognitive-cluster variant of the longevity-stack idea. Distinct from the wiki’s existing “four-peptide forever stack” (MOTS-c + Epithalon + BPC-157 + Thymosin Alpha-1, which targets mitochondrial + genomic + repair + immune biology) — Trigili’s stack targets cognitive/cortisol/blood-brain-barrier biology:

Order Peptide Trigili’s role for it Trigili’s dosing
1 Epithalon Cell-level reset (telomeres + pineal) 2–10 mg/day SubQ, 20–45 days, 2–3×/yr
2 Pinealon Blood-brain-barrier oxidative-stress protection 8–10 mg/day, ~21 days, 2–3×/yr — “right after finishing an Epitalon cycle. You can run them parallel simultaneously.”
3 Semax BDNF + NGF upregulation (neuroprotection + cognitive) 300–400 mcg split AM + PM, 21–30 days on / off
4 Selank Cortisol regulation + nervous-system grounding 300–400 mcg split, runs alongside Semax

Protocol-hygiene rule: Trigili does NOT run all four simultaneously. He stages them so each cycle picks up where the previous one left off. This maps onto the KB’s existing sequence-don’t-stack-simultaneously discipline for the bioregulators-khavinson-cluster.

How this sits alongside the existing four-peptide forever stack: the two are complementary longevity clusters targeting different presenting complaints:

  • Cognitive-focused cluster (Trigili): Epitalon + Pinealon + Semax + Selank — for burnout, chronic cognitive fog, stimulant dependence, sleep + emotional-regulation collapse.
  • Metabolic + repair cluster (one practitioner/wiki): Epitalon + MOTS-c + BPC-157 + Thymosin Alpha-1 — for metabolic aging, tissue repair, immune restoration, mitochondrial function.

Both share Epitalon as the anchor. The two clusters are not mutually exclusive — a longevity-focused user could cycle through both across a year, staggered.

Protocol as used by the community

Dose: 5–10 mg SubQ per day

Duration: 10–20 consecutive days (block dosing — unlike most peptides which are used weekly for months)

Cycle frequency: 1–2 times per year is dominant; some longevity-focused users do quarterly

Why block dosing? This follows the Khavinson research model — the original epithalon research used concentrated short-duration daily dosing rather than ongoing weekly use. Community has adopted this pattern as the established norm.

Side effects

Very mild.

  • Paradoxical insomnia at higher doses — documented by Fred Cloud; dose-dependent; resolves on reduction
  • Vivid dreams early in cycle — typically not distressing; usually resolves
  • Non-response (40–50%) — higher than most peptides; described as neutral, not adverse; no rebound
  • No dependency, withdrawal, or tolerance documented

How it compares to DSIP for sleep

Both improve sleep architecture. The distinction:

  • DSIP: More acute, dose-for-dose sleep deepening effect; used nightly during cycles
  • Epithalon: Block-dosed for 10 days; sleep benefit may be mediated by pineal gland / melatonin axis restoration; also carries the longevity mechanism that DSIP doesn’t have

Many longevity-focused users run both at different times of year.

Cross-references

  • [DSIP](/peptides/dsip/) — alternative/complementary for sleep architecture
  • [SS-31 (Elamipretide)](/peptides/ss-31/) · [MOTS-c](/peptides/mots-c/) — “mito stack” often combined with epithalon in longevity protocols
  • *circadian-sleep* — the circadian and melatonin axis context

Commercial note

Corrected 2026-08-01 — the previous version of this note routed Epithalon to Alyve, which does not carry it. The current OHM vendor routing:

  • Primary: US Pure Peptides — use code OHM20 for 20% off. USP carries the 40 mg lyophilized vial with an ISO 17025-accredited third-party COA, US-manufactured in West Palm Beach, FL.
  • Tertiary: BioLongevity — use code OHM-15 for 15% off. Fallback if USP is out.
  • Not in Alyve’s current 15-SKU catalog. If Alyve adds Epithalon in the future, this note gets updated and Alyve moves ahead of BioLongevity in the routing order — but as of 2026-08-01, USP is the primary path.

For a 4-amino-acid peptide that’s fast and cheap to synthesize — exactly the kind gray-market sellers cut corners on — identity-confirmed, COA-tested product is the whole game. A peptide-literate clinician is also a solid route (provider directory).

The wedge Build a personalized research protocol →

Skip ahead — search any peptide